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Rare copy-number variants (CNVs) have been implicated in autism and intellectual disability. These variants are large and affect many
genes but lack clear specificity toward autism as opposed to developmental-delay phenotypes.We exploited the repeat architecture of the
genome to target segmental duplication-mediated rearrangement hotspots (n ¼ 120, median size 1.78 Mbp, range 240 kbp to 13 Mbp)
and smaller hotspots flanked by repetitive sequence (n ¼ 1,247, median size 79 kbp, range 3–96 kbp) in 2,588 autistic individuals from
simplex and multiplex families and in 580 controls. Our analysis identified several recurrent large hotspot events, including association
with 1q21 duplications, which are more likely to be identified in individuals with autism than in those with developmental delay
(p ¼ 0.01; OR ¼ 2.7). Within larger hotspots, we also identified smaller atypical CNVs that implicated CHD1L and ACACA for
the 1q21 and 17q12 deletions, respectively. Our analysis, however, suggested no overall increase in the burden of smaller hotspots in
autistic individuals as compared to controls. By focusing on gene-disruptive events, we identified recurrent CNVs, including DPP10,
PLCB1, TRPM1, NRXN1, FHIT, and HYDIN, that are enriched in autism. We found that as the size of deletions increases, nonverbal
IQ significantly decreases, but there is no impact on autism severity; and as the size of duplications increases, autism severity signifi-
cantly increases but nonverbal IQ is not affected. The absence of an increased burden of smaller CNVs in individuals with autism
and the failure of most large hotspots to refine to single genes is consistent with a model where imbalance of multiple genes contributes
to a disease state.Introduction
Repeat architecture of the human genome predisposes
certain regions to nonallelic homologous recombination
(NAHR), resulting in copy-number variants (CNVs).1,2
Rare (<0.1% frequency) CNVs created by NAHR between
large (>10 kbp) segmental duplications (SDs), termed
‘‘genomic hotspots,’’ have been implicated in a range of
neurodevelopmental disorders, including intellectual
disability, autism (MIM 209850), epilepsy, and schizo-
phrenia (SCZD [MIM 181500]).3 Recent studies have sug-
gested that a large CNV burden is, in fact, associated with
lower measures for cognitive ability.4,5 However, the spec-
ificity of CNVs to autism susceptibility as opposed to
a broader developmental-delay phenotype is not clear.6
Although rare CNVs account for ~15% of pediatric neuro-
developmental disease, more than 30% of these cases
correspond to genomic hotspots—i.e., segments flanked
by high-identity SDs.7 In fact, most CNVs categorized as
‘‘unequivocally’’ pathogenic map to these genomic hot-
spots. Their predisposition to recurrent rearrangement
corresponds to a higher mutation rate, requiring fewer
cases and controls to be screened in order for statistical
significance to be reached. Most recurrent pathogenic
CNVs are large (>400 kbp), and the regions recurrently
deleted typically involve several to dozens of genes; there-1Department of Genome Sciences, University of Washington, Seattle, WA 9
Research Institute, National Institutes of Health, Bethesda, MD 20892, USA;
USA; 4Howard Hughes Medical Institute, University of Washington, Seattle, W
5These authors contributed equally to this work
*Correspondence: eee@gs.washington.edu
http://dx.doi.org/10.1016/j.ajhg.2012.12.016. 2013 by The American Societ
The Americfore, the genes responsible for neurodevelopmental disease
have not yet been discovered. Atypical pathogenic CNVs,
which are not mediated by SDs, will be much rarer and
require the detection of smaller events from exceedingly
larger populations.8–10 Despite advances in exome
sequencing,11–14 the discovery and genotyping of smaller
(<50 kbp) CNVs associated with disease have been chal-
lenging, especially in repeat-rich regions. Furthermore,
the discovery of extremely rare variants has precluded
replication and enrichment analysis for further genotype-
phenotype correlations.
One approach is to identify genomic regions that are
prone to recurrent rearrangements and under strong selec-
tion in the human population. Although other high-iden-
tity repeat sequences that are smaller than SDs have been
documented,15,16 their role in disease rearrangements
under the NAHR model has not been systematically
explored, especially for cases of sporadic and familial
autism. On the basis of the original model of NAHR and
the repeat architecture of the human genome, we identi-
fied 1,367 gene-rich regions capable, in principle, of recur-
rent copy-number variation. The sites ranged in size from
5 kbp to 5 Mbp, and most traversed or intersected genes.
We designed a customized targeted, high-density (one
probe every 50 bp to 1 kbp) microarray to screen individ-
uals with autism (from the Simons Simplex Collection8195, USA; 2Genetic Disease Research Branch, National Human Genome
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Table 1. Definition of Targeted Genomic Hotspots
Regions Total Sites
Size in Base Pairs Probe Spacing Number of
Genes Completely
Contained within
the CNV
Number of
Genes Disrupted
by CNV
BreakpointsTotal Size Median Max Min Median Max Min
SD hotspot 120 270,139,571 1,777,180 12,991,283 241,831 5,000 20,000 5,000 2,971 67
Microhotspot 410 12,565,293 32,068 55,726 7,018 641 1,115 140 143 145
Minihotspot 253 11,342,110 41,701 96,127 3,176 1,043 2,403 79 77 105
AluY hotspot 584 52,560,000 90,000 90,000 90,000 2,500 2,500 2,500 692 603
1,367 346,606,974 3,883 920[SSC] and Autism Genetic Resource Exchange [AGRE]) for
four purposes: (1) to assess genomic instability of 1,367
hotspot regions, including 120 SD-mediated hotspots,
253 minihotspots (flanked by smaller SD blocks), 410 mi-
crohotspots (flanked by identical pairs of >100 bp
sequences), and 584 Alu-mediated hotspots; (2) to identify
CNVs that are specific to autism as opposed to develop-
mental delay; (3) to determine whether smaller atypical
pathogenic CNVs could be identified within 17 genomic
regions previously associated with developmental delay
and autism; and (4) to characterize candidate genes disrup-
ted more often in autism cases than in controls.Subjects and Methods
Samples from Affected Individuals
Families with children affected with idiopathic autism (n ¼ 2,478)
were identified through the SSC.17 The SSC includes families with
nomore than one child with autism. The families were ascertained
through 12 data-collection sites across North America. The criteria
for inclusion require that a child meet the autism spectrum
disorder (ASD) diagnosis on the Autism Diagnostic Observation
Schedule (ADOS)18 and on the Autism Diagnostic Interview,
Revised (ADI-R)19 and that the child passes an expert clinical eval-
uation. Standardized head-circumference scores were calculated
on the basis of norms that Roche and colleagues20 established to
account for age and gender. A nonverbal IQ (NVIQ) greater than
35 is also required. Exclusion criteria consist of significant hearing,
vision, or motor problems, significant birth complications, or
a diagnosis of an ASD-related disorder, such as fragile X syndrome.
Individuals with up to a third-degree relative with ASD or a sibling
with features of ASD were also excluded. Diagnostic evaluations,
cognitive assessment, and phenotypic characterization were con-
ducted at each site, and data collection, entry, and validation
methods were standardized across sites to ensure reliability of
sample collection. In addition, affected probands (n ¼ 719) from
multiplex families with autism were identified through AGRE.21
All family members were tested with ADOS and ADI-R, and cyto-
genetic analyses were performed so that gross chromosomal
abnormalities could be ruled out. All individuals from this study
were recruited after appropriate approval and informed consent
were obtained from all participants.
Controls
Control populations were obtained from two cohorts. The
National Institute of Mental Health (NIMH) control cohort22 con-222 The American Journal of Human Genetics 92, 221–237, Februarysisted of 207 DNA samples obtained from the Rutgers University
Cell and DNA Repository. These individuals were ascertained
through an online self-report based on the Composite Interna-
tional Diagnostic Instrument short-form (CIDI-SF).23 Those who
didnotmeetDSM-IV criteria formajor depression, denied a history
of bipolar disorder or psychosis, and reported exclusively Euro-
pean origins were included.24,25 In addition, 373 individuals
from ClinSeq, designed to study a spectrum of atherosclerotic
disease, were included.26 The frequency of the identified CNVs
was also assessed from an expanded set of control CNV calls
derived from 8,329 individuals assessed via SNP microarrays for
the 120 SD-mediated hotspots8 and from a subset of this cohort
(n¼ 2,090 individuals), characterized through theWellcome Trust
Case-Control Consortium (WTCCC) by the high-density Illumina
1.2M SNP microarray for smaller hotspot regions and candidate-
gene events.27 No cognitive assessments were available for these
controls, who were deemed normal, healthy volunteers. As such,
they do not represent disease-matched controls but rather popula-
tion controls.
Hotspot Definition and Microarray Design
On the basis of the original model of NAHR, where the presence
of high-identity repeat sequences can promote unequal cross-
over and lead to deletions or duplications of the intervening
unique sequence of DNA, we identified 1,367 regions, including
(1) regular nonredundant hotspots, defined as regions flanked by
SDs (R95%, R10 kbp), whose size ranged from 50 kbp to 5 Mbp
and which were mapped within 120 genomic sites (Figures S1–
S3 available online);28,29 (2) minihotspots, defined here to corre-
spond to 1–100 kbp intervals of unique sequence flanked by
smaller (1–10 kbp) SDs with R90% sequence identity; (3) micro-
hotspots, defined here as 1–50 kbp regions that contain at least
one gene and are flanked by nearly perfect-identity repeats (one
mismatch) of at least 100 bp in length; and (4) Alu hotspots,
defined as events identified within 50 kbp nonoverlapping
genomic windows containing at least 15 kbp of Alu elements
(specifically AluY) and one or more RefSeq genes. We also
surveyed CNVs in regions (n ¼ 250) that were enriched for
highly conserved bases (on the basis of Genomic Evolutionary
Rate Profiling scores) and contained 15 kbp or more of Alu
repeats within a 50 kbp window.30 In total, our customized mi-
croarray (Agilent 2 3 400K) targeted 1,367 sites totaling ~346
Mbp of genomic sequence. Probe density varied from one probe
every 640 bp to 5 kbp depending on size (Table 1, Figure S2). For
smaller hotspots, we included an additional 5–20 kbp of flank-
ing sequence to improve sensitivity and boundary definition.
We interrogated 3,883 genes for dosage sensitivity and 920
genes for gene breakage as a consequence of CNVs within the7, 2013
1,367 hotspots (Table S1). In addition, a backbone of probes
(including probes used by the International Standards for Cyto-
genomic Arrays [ISCA] Consortium microarray design31), at
a density of one probe every 14.5 kbp, were distributed across
the genome.CNV Discovery and Genotyping
Array comparative genomic hybridization (CGH), washing, and
analysis were performed according to the manufacturer’s instruc-
tions. We used sex-matched reference samples with NA12878
(CEU [Utah residents with ancestry from northern and western
Europe from the CEPH collection] female) as the reference for
females and NA18507 (YRI [Yoruba in Ibadan, Nigeria] male) as
the reference for males (from Coriell). Microarray hybridization
data for each probe was computed with Agilent Feature Extraction
software, converted to log2 ratio values, and uploaded to an in-
house structured SQL database. We applied a first-pass quality-
control (QC) filter of >0.23 derivative log-ratio threshold per
sample (per the manufacturer’s instructions). CNV calling was
then performed by targeted genotyping and/or Agilent’s Aberra-
tion Detection Method 2 (ADM-2) algorithm,32 built within the
Agilent Genomic Workbench software, requiring an absolute
log2 ratio cutoff of 0.5 with at least three probes. In brief, we per-
formed targeted genotyping of hotspots by calculating the
average log2 intensity ratios of a region (Figures S3 and S4). By
using chromosome-specific means and standard deviations, we
generated a normalized log2 intensity ratio of each hotspot for
each sample (z score).8 We plotted and manually visualized
samples with an absolute z score R 1.5 for each targeted region
to remove false-positive calls. Events were considered to be medi-
ated by smaller repeats if the identified CNV had a reciprocal over-
lap of 50% of its length with the targeted micro- or minihotspot
sites (Figures S3 and S4). Events with one or both breakpoints
mapping within flanking repeat sequences were categorized as
‘‘hotspot associated’’ or ‘‘hotspot mediated,’’ respectively
(Figure S3). Detection of CNVs outside of hotspots, in the
genomic backbone, was performed with the ADM-2 algorithm.
We applied additional filters (<50% SD content, <0.3 standard
deviation of log2 ratios across chromosomes for a given sample,
<1% frequency in the controls) to remove false-positive calls
and copy-number polymorphisms (Figure S5). Because most of
these CNVs are not recurrent and do not share common break-
points, we have limited power to derive statistically significant
associations. Furthermore, smaller atypical events within
disease-associated hotspots and CNVs involving autism candidate
genes, compiled by the Simons Foundation Autism Research
Initiative (SFARI) gene database and from recent exome
sequencing projects, were identified by both targeted genotyping
and the ADM-2 algorithm. We manually curated all identified
CNVs by loading the log-transformed signal intensities on
a custom UCSC Genome Browser. CNVs within the population
control cohort were characterized in a previous study.33 Valida-
tion experiments were performed on a NimbleGen array with
135K probes as described previously.4Results
We initially screened 2,478 individuals ascertained for ASD
from the SSC, 719 individuals from the AGRE collection,
and 580 controls from the ClinSeq and NIMH collections.The AmericAll analyses of copy-number variation were performed by
a custom microarray with a high density of probes
(640 bp to 5 kbp) targeted to 1,367 regions with a suscep-
tible genomic architecture and a median probe spacing of
14.5 kbp in the genomic backbone. After QC measures,
a total of 2,588 autism and 580 control samples were
included for an initial analysis (Table S2). We determined
the performance of our array by assessing inheritance for
a subset (n ¼ 550) of CNVs and performed validation
experiments by a second customized NimbleGen array.
We estimated a high sensitivity and specificity (>99%) of
the array to detect events >10 kbp in the targeted regions
and >250 kbp in the genomic backbone. In addition, to
assess the frequency of variants as well as to exclude
copy-number polymorphisms, we genotyped candidate
sites on an expanded set of 8,329 population controls for
SD-mediated genomic hotspots8 and a subset of these
controls for smaller CNVs (n ¼ 2,090 WTCCC controls)
genotyped by SNP microarray data (see Subjects and
Methods).
Rare Recurrent Rearrangements within SD-Mediated
Genomic Hotspots
We initially focused on rare recurrent CNVs within
genomic hotspot regions; these corresponded to 120
regions in the human genome and were flanked by large,
highly identical SDs.28 As expected, the burden of these
large CNVs was higher in cases than in controls (2.8%,
72/2,588 autism cases versus 1.3%, 108/8,329 controls;
p¼ 7.203 107, OR ¼ 2.18); there was a slight bias toward
duplications (42/72) versus deletions (30/72). Inheritance
data from available parental samples showed that 52%
(36/69) of these CNVs were de novo variants and that
the remainder were inherited (16 maternal, 17 paternal)
(Table S3). These CNVs corresponded to 29/120 (24%)
genomic hotspots. Mutations in 17 of these, including
16p11.2, 1q21.1, 15q13.3, 17q12, and 17p12 chromo-
somal regions, were previously known to be associated
with disease (Figure 1; Table S3).
We compared the prevalence of various genomic disor-
ders in this set of clinically defined individuals with
autism to the frequency observed in a more broadly
defined set of children with developmental delay (n ¼
31,518) and a large population control set (n ¼
8,329).8,34 In most cases the frequencies of specific
genomic disorders were comparable, although some differ-
ences were noted. We found a significant enrichment of
1q21.1 duplications (MIM 612475) in autism compared
to developmental delay (Fisher’s exact test, p ¼ 0.01;
OR ¼ 2.7; 95% CI, 1.1–5.9). No specific clinical features
served as a hallmark of these duplications, ruling out any
autism-specific syndromes. Furthermore, we observed
duplications of the Williams-Beuren syndrome (WBS
[MIM 194050]) region in the autism cohort (4/2,588,
0.15%), as previously reported,35 that were not signifi-
cantly enriched in autism compared to developmental
delay (31/31,518, 0.10%; p ¼ 0.27; OR ¼ 1.5). Otheran Journal of Human Genetics 92, 221–237, February 7, 2013 223
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Figure 1. Recurrent Large CNVs in Indi-
viduals with Autism versus Developmental
Delay
Data from individuals with developmental
delay (n ¼ 31,518) were derived from
recently published reports.8,34 CNVs
(>400 kbp) enriched among children
with autism (blue asterisk) as opposed to
developmental delay (red asterisk) and
vice versa.recurrent CNVs were more commonly observed in chil-
dren diagnosed with developmental delay as opposed to
autism. For example, 22q11.2 deletions (Velocardiofacial
DiGeorge syndromes [MIM 188400]) (p ¼ 3.11 3 1011,
OR ¼ 7.9, 95% CI, 2.6–66) and nonrecurrent 9q34 dele-
tions (Kleefstra syndrome [MIM [610253]) (p ¼ 0.04,
OR ¼ 5.34, 95% CI, 1.1–Inf) were significantly associated
with developmental delay as opposed to autism (Figure 1).
Trends toward association with developmental delay were
observed for the 1q21.1 deletion (p ¼ 0.07, OR ¼ 3.04,
95% CI, 0.9–Inf) and the 16p12.1 deletion (p ¼ 0.07,
OR ¼ 4.52, 95% CI, 0.92–Inf).
Interestingly, we identified 12 regions harboring SD-
mediated (e.g., 10q11.23, 11q14.3, 5p15.33, 12p12.1,
7q11.23, and 2q11.2) or SD-associated (e.g., 2q12.1,
9p24, and 16q22) events not previously reported in
autism. In a subset of these regions, CNVs were also iden-
tified in children with developmental delay (out of
15,767 cases)8 but not in controls (out of 8,329 controls),
although this result was not statistically significant
(Figure S6). Interesting regions include a 1.6 Mbp recurrent
10q11.23 duplication (paternally inherited in SSC proband
13465.p1), which was previously reported in a case study
of children with developmental delay and intellectual
disability;36 a 940 kbp recurrent deletion (two paternally
inherited in SSC probands 12550.p1 and 14043.p1) of
the 2q11.2 locus; 2 Mbp deletions of the region distal to
theWBS region in autism (a de novo event in SSC proband
14484.p1) and developmental delay cases not observed in
controls; and SD-associated events at the 16q22.2 locus,
spanning axonemal central pair apparatus protein (HY-
DIN), in three children with autism but not in children
with developmental delay or controls.
Phenotypic Trends: Duplications versus Deletions
In individuals with autism, we observed an apparent
enrichment of reciprocal duplications (e.g., 1q21.1 and224 The American Journal of Human Genetics 92, 221–237, February 7, 2013WBS) corresponding to microdele-
tion hotspots associated with devel-
opmental delay (Figure 1). With the
phenotypic data collected for the
SSC samples,11–13,17,37 we investi-
gated the phenotypic features of
affected individuals with large
CNVs and, more specifically, con-
trasted those carrying deletionswith those carrying duplications. A significant difference
was observed between individuals with large CNVs and
individuals with smaller events in the restricted/repetitive
interests/behaviors domain (multivariate ANOVA,
F(3,1887) ¼ 4.7, p ¼ 0.003, h2 ¼ 0.007), but no differ-
ences in the social or communication domains were
observed (Figure S7). Furthermore, post hoc comparisons
of the ADI-R data showed significantly higher mean
scores (p ¼ 0.007), indicating more impairment with
respect to restricted or repetitive interests in children
with duplications than in those with deletions. Notably,
individuals with deletions had lower mean scores in
this domain, indicating that they had less impairment
(p ¼ 0.016) than individuals without any identified
mutations.
Head circumference was also contrasted in individuals
with deletions and duplications (Table S4). Children
with 16p11.2 deletions (mean z score ¼ 2.3, SD ¼ 1.6)
had significantly larger heads than children with 16p11.2
duplications (mean z score ¼ 0.2, SD ¼ 0.9; t(11) ¼
3.56, p ¼ 0.004), consistent with previous reports.38 Even
though the mean head circumference of the ASD individ-
uals examined in this study was 0.69 standard deviations
larger than that of the normative population, the individ-
uals with 16p11.2 deletions (MIM 611913) were, on
average, 1.22 standard deviations above the mean of the
ASD sample set. Likewise, the head circumference of
individuals with 16p11.2 duplications (MIM 614671)
was, on average, 0.72 standard deviations below the ASD
mean.
To further untangle the relationship between dupli-
cations and deletions in relation to autism or develop-
mental delay phenotypes, we calculated correlations
between CNV size across all genomic regions and
NVIQ, as a measure of developmental delay and autism
severity (as measured by the calibrated severity scale39). A
significant negative correlation between the size of the
Figure 2. Phenotypic Features of Deletions and Duplications as a Function of Size
The scatter plot demonstrates that as the size of the deletion increases, nonverbal IQ significantly decreases, whereas as the size of dupli-
cation increases, autism severity significantly increases.event and NVIQ was observed for the deletions (Pearson
correlation, R(222) ¼ 0.24, p < 0.0001) but not for the
duplications (R(317) ¼ 0.06, p ¼ 0.257). In contrast,
a significant correlation was observed between event
size and autism severity for the duplications (Spearman
correlation, rs (301) ¼ 0.13, p ¼ 0.02) but not for the dele-
tions (rs (212) ¼ 0.02, p ¼ 0.86) (Figure 2). It is possible
that the observed relationships between CNV duplication
size and severity and between CNV deletion size and
NVIQ are driven by a few key regions but, given the limited
sample sizes in each region, it is difficult to draw definitive
conclusions (Table S5).
With specific regard to regions showing enrichment of
duplications in autism versus developmental delay, the
median and standard deviations for NVIQ were 94 and
31.9 for 1q21.1 duplications and 86 and 31.9 for WBS
duplications (MIM 609757), respectively. Interestingly,
the majority of probands carrying these duplications
scored above the average for NVIQ. These results suggest
that increased dosage of genes within certain genomic hot-
spots might enhance the severity of the autism phenotype
but that haploinsufficiency might lead to reduced NVIQ
associated with developmental delay.The AmericPutative Smaller Hotspots
We next focused on 1,247 genomic regions that are poten-
tially predisposed to unequal crossover events because
they are flanked by smaller repeat elements (see Subjects
and Methods; Figure S1). The flanking sequence of these
hotspots included smaller (1–10 kbp) SDs (minihotspots),
perfectly identical sequences at least 100 bp in size (micro-
hotspots), or regions enriched for Alu repeats. These
smaller hotspots potentially affect 1,765 genes—of which
853 would be disrupted if the CNVs occurred (Table S1).
We performed targeted CNV discovery within 1,106 of
these smaller hotspots, which could be accurately geno-
typed on our microarray, on the same sample set (see
Subjects and Methods). We identified CNVs in 22% (83/
378) of microhotspots, 6% (13/227) of minihotspots, and
4% (21/501) of AluY hotspots (Tables S6–S9). After
excluding variants observed in controls by using the
same microarray platform (n ¼ 580) or >0.1% of the
expanded set of 2,090 WTCCC controls, we found that
3% (76/2,588) of the cases carried smaller hotspot-medi-
ated or hotspot-associated events (Table S10). We assessed
the inheritance status of these events and found that the
majority of the tested events were transmitted froman Journal of Human Genetics 92, 221–237, February 7, 2013 225
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Figure 3. Properties of CNV Hotspots
(A and B) Frequency of deletions (A) and duplications (B) at different size ranges is shown for SD-mediated hotspots and smaller (micro,
mini, and AluY) hotspots. Although no enrichment for smaller non-SD hotspots is observed among autistic children, a significant
enrichment for larger, SD-mediated CNVs is observed. An asterisk denotes a significant difference (p < 0.05) in cases compared to
controls via a Mann-Whitney t test.
(C and D) Sequence properties of genomic hotspots are shown. A comparison of size (C) and sequence identity (D) of repeats
flanking ‘‘active’’ hotspots versus ‘‘inactive’’ genomic hotspots. The error bars indicate the minimum and maximum range of the data
points.a carrier parent (60/70, 86%). All ten de novo events were
greater than 100 kbp in size. We found no significant
enrichment or global increase in burden among the
smaller hotspots in cases compared to controls (p ¼ 0.13,
OR ¼ 1.2) (Figure 3A; Table S9). Although none of these
genes have been reported to be associated with autism
and no single locus reaches statistical significance in this
study, functional analysis suggests coexpression and inter-
actions in metabolic pathways among several of these
genes (Figure S8).
We compared the structure and sequence properties of
repeat sequences flanking active and inactive hotspots as
defined by this study. We categorized hotspots as predis-
posing and nonpredisposing for NAHR-mediated rear-
rangements on the basis of the orientation of the SDs
within the human reference genome.7 Although all
microhotspots were chosen to contain the predisposing
structure, we found that the repeat sequences flanking
active microhotspots were larger (median size 284 bp;
p ¼ 0.0001, Mann Whitney U test) and had higher226 The American Journal of Human Genetics 92, 221–237, Februarysequence identity (median sequence identity 99.29%;
p ¼ 0.0001, Mann-Whitney U test) than those flanking
inactive hotspots (median size and sequence identity
244 bp; 99.18%) (Figure 3B). We note that the high corre-
lation between the size of the repeats and sequence iden-
tity is due to ascertainment of these hotspots (see Subjects
and Methods). We curated all events mapping within the
120 regular hotspots by assessing the 2,588 autism
samples analyzed in this study and the previously reported
15,767 cases with developmental delay.8 As observed
previously,8 we found both the size and identity of SDs
flanking active hotspots to be greater than those of SDs
flanking inactive hotspots. However, when minihotspots
were analyzed for sequence properties, we found that the
activity within minihotspot sites was dependent upon
the size (hotspot median size and sequence identity
2,198 bp; 93.3%) of the flanking repeat (p ¼ 0.021,
Mann-Whitney U test) and not on the extent of sequence
identity (p ¼ 0.55, Mann-Whitney U test); this is in
contrast to results for inactive sites (coldspot median size7, 2013
and sequence identity 1,459 bp; 93.4%) (Figure 3B). No
events were identified in minihotspot regions that had
a nonpredisposing or protective genomic architecture,
suggesting no alternative SD structure within these
regions.40 Overall, our results suggest that, apart from pre-
disposing orientation, the size of the repeats and high
sequence identity are major determinants of activity of
NAHR hotspots.
Atypical CNVs within Candidate Regions
In an effort to detect smaller events within known patho-
genic regions, we targeted 17 larger, disease-associated hot-
spot CNVs with a probe density of one probe every 750 bp.
We screened individuals by array CGH in order to refine
these loci to one or a few candidate genes. Within the
autism cohort (1.4% of cases), we discovered and validated
36 smaller deletions (n ¼ 23) and duplications (n ¼ 13)
that were not detected in our control cohort (n ¼ 580)
and were at <0.1% frequency among the 2,090 WTCCC
controls (requiring R10 probe coverage) (Table 2). Inter-
esting candidates specific to the autism cohort include
a 323 kbp deletion encompassing chromodomain helicase
DNA binding protein 1-like (CHD1L [MIM 613039])
within the chromosome 1q21.1 deletion region (MIM
612474) in SSC proband 12719.p1 (Figure 4A); a 132 kbp
tandem duplication of neuregulin-3 (NRG3 [MIM
605533]) exon 4 at 10q23.1 in SSC proband 13889.p1;
and a 304 kbp deletion of acetyl-CoA carboxylase alpha
(ACACA [MIM 200350]) within the 17q12 microdeletion
region in SSC proband 11234.p1 (Figure 4B). All atypical
events detected were inherited from an apparently unaf-
fected parent. In addition, we also identified two individ-
uals (SSC proband 12132.p1 and AGRE proband
AU084503) with inherited in-frame deletions of exons 3
and 4 of BBS4 (MIM 600374), a gene implicated in the
autosomal-recessive Bardet-Biedl syndrome (MIM
209900), although the size of the event was too small to
assess in the WTCCC controls. At the chromosome
15q13.3 locus, we detected an enrichment (5/2,588) for
deletions of TRPM141,42 (MIM 603576) in individuals
with autism (SSC proband 13686.p1 and AGRE probands
AU0316301, AU2275301, AU079904, and AU1006301)
compared to controls (0/2,670 controls; Fisher’s exact
test p ¼ 0.029) (Figure 5A). Interestingly, all TRPM1 dele-
tions were inherited, and one individual inherited the
deletion from both parents and thus had a homozygous
deletion.
Targeted Discovery of CNVs in ‘‘Autism" Genes
Because our custom microarray also carried a suitable
(14 kbp density) coverage of probes across the genomic
backbone, we performed targeted discovery of CNVs
affecting known autism candidate genes (n ¼ 430 genes).
The set included genes reported in recent exome
sequencing studies11–13 as well as those curated in autism
databases. Of the 253 candidate genes that we could geno-
type with high specificity, 76 showed evidence of copy-The Americnumber variation; 60 of these genes were enriched in or
exclusive to the autism cohort as opposed to controls
(Table 3, Figure 5; Table S11). Of these autism-enriched
candidate genes, 55 were directly ‘‘broken’’ or disrupted
by a CNV, which in some cases was characterized as a hot-
spot-mediated or -associated event. Although we observed
no significant difference in overall CNV burden of these
autism-candidate genes between individuals with autism
(8.5%; 221/2,588) and controls (6.9%; 40/580), several
genes stood out as being enriched for CNVs in cases versus
our complete set of controls (n ¼ 2,670; 580 in this study
and 2,090 WTCCC controls) (Figures 5 and S9). Some
examples include dipeptidyl peptidase 10 (DPP10 [MIM
608209]) (p ¼ 0.029, Fisher’s exact test) (Figure 5B),
a gene that is involved in synaptogenesis and which
was previously reported in a CNV study of autism;43 neu-
rexin 1 (NRXN1 [MIM 600565]) (p ¼ 0.032) (Figure 5C),
a gene encoding a cell-adhesionmolecule previously impli-
cated in numerous neurocognitive disorders, including
autism;44 phospholipase C, beta 1 (PLCB1 [MIM 607120])
(Figure 5D), a gene implicated in epilepsy45and schizo-
phrenia;46 fragile-histidine triad (FHIT [MIM 601153])
(Figure 5E), implicated in a genome-wide association study
for anxiety;47 methyl-CpG binding domain protein 5
(MBD5 [MIM 611472]) (Figure 5F), which lies within chro-
mosomal region 2p23.1 and was previously implicated in
autism, epilepsy, and developmental delay;48,49 and Par-
kinson protein 2 (PARK2 [MIM 602544]) (p ¼ 0.009),
a gene associated with Parkinson disease and previously
implicated in autism.50 Interestingly, we also observed
three large SD-associated CNVs (one deletion and two
duplications) that include HYDIN (MIM 610812) on chro-
mosome 16q22 (Figure 6; described above). Of the events
affecting HYDIN, two were de novo, and one was inherited
in a multiplex autism family where the CNV segregated
with disease. A majority (88.2%; 149/169) of the autism-
enriched gene-specific events identified were inherited
from unaffected parents. The 20 de novo CNVs were all
greater than 50 kbp in size and were observed in 17 genes,
including NRXN1, FHIT, and HYDIN, all three of which
had recurrent events.Discussion
In this study, we systematically assessed regions prone to
recurrent copy-number variation in 2,588 children with
ASD—this is one of the largest studies to date for clini-
cally defined autism. Many of the smaller regions tar-
geted in this study would have been previously unassay-
able35 because of the paucity of markers on standard
commercial SNP microarrays. As expected, we observed
a significantly more CNVs (total ¼ 72 events) among
the larger 120 hotspot regions that were flanked by large
SDs than we did in controls (Figure 1; Table S3). Almost
half of these larger events were de novo (Figure S10).
Although 10.6% (117/1,106) of our smaller regionsan Journal of Human Genetics 92, 221–237, February 7, 2013 227
Table 2. Atypical Exon-Disrupting Events of Disease-Associated Hotspot Regions in Children with Autism
Region
Genomic
Coordinates (hg18) Sample Size (bp) Genes Event Inheritance
Case
Probes
Control
Probes
Control
Eventsa p Value
1q21.1 chr1: 145,182,393–
145,442,505
12719.p1 260,112 CHD1L,
LINC00624
del maternal 323 118 0 n/a
1q21.1 chr1: 145,302,783–
145,354,227
12345.p1 51,444 LINC00624 del maternal 59 4 n/a n/a
1q21.1 chr1: 145,302,783–
145,354,227
11712.p1 51,444 LINC00624 del maternal/
paternal
59 4 n/a n/a
3q29 chr3: 197,762,959–
197,767,300
14045.p1 4,341 WDR53 del paternal 7 3 n/a n/a
3q29 chr3: 198,022,697–
198,054,675
13144.p1 31,978 PAK2 dup paternal 47 44 0 n/a
3q29 chr3: 198,682,714–
198,836,982
AU1087301 154,268 BDH1 dup paternal 221 75 0 0.242
3q29 chr3: 198,682,714–
198,836,982
13746.p1 154,268 BDH1 dup maternal 221 75 0 0.242
10q23 chr10: 81,575,201–
81,959,837
13214.p1 384,636 MBL1P1, SFTPD,
LOC219347,
C10orf57,
PLAC9, ANXA11
del maternal 534 247 1 0.301
10q23 chr10: 81,809,415–
81,833,598
13582.p1 24,183 LOC219347,
C10orf57
del paternal 35 6 n/a n/a
10q23 chr10: 81,824,603–
81,834,112
12969.p1 9,509 LOC219347,
C10orf57
del paternal 16 3 n/a n/a
10q23 chr10: 82,084,686–
82,106,599
12378.p1 21,913 DYDC1 dup maternal 34 9 n/a n/a
10q23 chr10: 82,084,686–
82,106,599
13634.p1 21,913 DYDC1 dup paternal 34 9 n/a n/a
10q23 chr10: 82,084,686–
82,106,599
14055.p1 21,913 DYDC1 dup maternal 34 9 n/a n/a
10q23 chr10: 82,084,686–
82,106,599
14343.p1 21,913 DYDC1 dup maternal 34 9 n/a n/a
10q23 chr10: 82,084,686–
82,106,599
11545.p1 21,913 DYDC1 dup maternal 34 9 n/a n/a
10q23 chr10: 82,084,686–
82,106,599
13611.p1 21,913 DYDC1 dup maternal 34 9 n/a n/a
10q23 chr10: 82,084,686–
82,106,599
AU1763301 21,913 DYDC1 dup maternal 34 9 n/a n/a
10q23 chr10: 82,359,933–
82,366,203
14348.p1 6,270 SH2D48 del paternal 10 5 n/a n/a
10q23 chr10: 84,593,836–
84,680,305
13889.p1 86,469 NRG3 dup maternal 132 40 0 n/a
15q13.3 chr15: 29,142,646–
29,178,949
13686.p1 36,303 TRPM1 del maternal 54 18 0 0.029
15q13.3 chr15: 29,142,646–
29,178,949
AU0316301 36,303 TRPM1 del paternal 54 18 0 0.029
15q13.3 chr15: 29,142,646–
29,178,949
AU2275301 36,303 TRPM1 del paternal 54 18 0 0.029
15q13.3 chr15: 29,142,646–
29,178,949
AU079904 36,303 TRPM1 del maternal/
paternal
54 18 0 0.029
15q13.3 chr15: 29,176,938–
29,188,508
AU1006301 11,570 TRPM1 del maternal 17 6 n/a n/a
15q24.1 chr15: 70,788,521–
70,793,560
12132.p1 5,039 BBS4 del maternal 5 1 n/a 0.242
(Continued on next page)
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Table 2. Continued
Region
Genomic
Coordinates (hg18) Sample Size (bp) Genes Event Inheritance
Case
Probes
Control
Probes
Control
Eventsa p Value
15q24.1 chr15: 70,788,521–
70,793,560
AU084503 5,039 BBS4 del paternal 5 1 n/a 0.242
15q24.2 chr15: 74,294,283–
74,297,672
AU1228303 3,389 ETFA del paternal 15 2 n/a n/a
16p13.11 chr16: 15,476,243–
15,515,874
13215.p1 39,631 C16orf45 del paternal 61 19 0 n/a
16p11.2 chr16: 29,961,147-
29974677
14004.p1 13,530 ALDOA del maternal 16 6 n/a n/a
17q12 chr17: 32560142-
32732763
11234.p1 172,621 ACACA del maternal 304 92 0 n/a
17q12 chr17: 33,179,017–
33,351,760
11002.p1 172,743 HNF1B (TCF2),
LOC284100
dup maternal 282 68 0 n/a
22q11.21 chr22: 17,413,909–
17,429,856
12686.p1 15,947 DGCR2 del paternal 26 6 n/a n/a
22q11.21 chr22: 17,703,043–
17,719,750
11599.p1 16,707 HIRA del maternal 17 6 n/a n/a
22q11.21 chr22: 19,455,582–
19,462,562
12878.p1 6,980 SERPIND1 del paternal 11 7 n/a n/a
22q13.31 chr22: 46,964,885–
47,079,942
13698.p1 115,058 MIR3201 dup paternal 163 95 0 0.242
22q13.32 chr22: 47,131,579–
47,224,607
AU1678301 93,028 MIR3201 dup maternal 134 75 0 0.242
22q13.32 chr22: 48,026,222–
48,302,803
13722.p1 276,581 C22orf34 del maternal 406 284 1 n/a
None of the above events were observed in controls assayed with our custom microarray (n ¼ 580).
aControl events, defined here as atypical CNVs that overlap with the reported event, were identified from population controls ran on Illumina 1M SNP array plat-
form (n ¼ 2,090). Control CNVs were assessed only if coverage exceeded ten probes on the SNP array.showed evidence of copy-number variation consistent
with unequal crossing over of flanking repetitive DNA,
we observed no enrichment of smaller CNVs when we
compared individuals with autism to controls (Table
S9). In contrast to the larger hotspots, in these smaller
regions the majority (86%) of the CNVs were transmitted
from unaffected parents. One possibility is that the 1,866
genes within these smaller hotspot regions are simply
irrelevant to the etiology of autism. We note, for
example, a slight functional enrichment of genes associ-
ated with metabolism within these smaller hotspot
regions (Figure S8). Alternatively, it might be that larger
events, because of their potential to affect multiple genes,
are more likely to have a larger impact during neurode-
velopment, consistent with an oligogenic model.6,51–53
Smaller CNVs disrupting a single gene might not be suffi-
ciently deleterious and might, therefore, be more likely to
be transmitted within the human population without
adverse effect.
The large number of autistic individuals screened in this
study allowed us to make some novel insights with respect
to larger recurrent CNVs. We found that the chromosome
1q21.1 duplication, 16p11.2 deletion, and 16p11.2 dupli-
cation (Table S3) are the most prevalent CNVs significantly
enriched in individuals with autism versus controls.The AmericDespite the fact that less than 25% of the autistic individ-
uals screened in this study would qualify as having intel-
lectual disability,17 the pattern and frequency of various
genomic disorders is remarkably similar to recent large-
scale screens of children with developmental delay
(Figure 1).8,34 Nevertheless, some differences in frequency
were noted. We found significant enrichment of 1q21.1
duplications (a novel association for autism) and a trend
for WBS duplications (as reported in Sanders et al.35) in
autistic children compared to those classified as develop-
mentally delayed. No distinguishable additional pheno-
types for these variants in cases could be deduced from
the available clinical descriptions. Of note, most of the
probands carrying these duplications have average to
above-average NVIQ. Conversely, 22q11.2 and 9q34 dele-
tions were significantly associated with developmental
delay but not with autism. Although it appears there are
no recurrent CNVs specific to autism, there are biases in
frequency.
Our analysis also suggests that the type of CNV (i.e.,
duplication or deletion) has an important influence on
phenotypic outcome among individuals with autism. As
shown previously,4,35 increasing size of deletions correlates
with a significant decrease in NVIQ; the same effect,
however, is not observed for increasing size of CNVan Journal of Human Genetics 92, 221–237, February 7, 2013 229
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Figure 4. Atypical Copy-Number Variants within Disease-Asso-
ciated Regions
Large recurrent CNVs were identified within the 1q21.1 (A) and
17q12 (B) microdeletion loci in autism cases. Private atypical dele-
tion events reveal potential candidate genes CHD1L (A) and
ACACA (B), highlighted by the dashed box. Blue (duplication)
and red (deletion) histograms depict log2 relative hybridization
signals. SDs flanking the larger recurrent events are mapped at
the top.
230 The American Journal of Human Genetics 92, 221–237, Februaryduplications (Figure 2). In contrast, we find that as the size
of duplications increases, autism severity increases as
measured by the calibrated autism severity score (p ¼
0.02) and repetitive or stereotypic behavior (ADI criteria)
(p ¼ 0.007). The basis for this difference is unclear, but
it might be that an increase in gene dosage perturbs
neurodevelopmental processes, whereas haploinsuffi-
ciency disrupts it more severely and leads to reduced
NVIQ and developmental delay. These findings are also
consistent with the reciprocal nature of some CNVs,
such as those in the WBS and 1q21.1 regions, where
duplications are enriched in autism cases but deletions
are found primarily among children with developmental
delay.
In this study, we also targeted 17 disease-associated
regions at high-probe density (1 probe per 650 bp) in an
attempt to identify smaller atypical events that might
help refine a smaller region of overlap and thereby
pinpoint specific genes. Within the 1q21.1 deletion
region, we identified a 323 kbp deletion involving
CHD1L (Figure 4A). This is a compelling candidate gene
because it is related to CHD8 (MIM 610528), one of the
genes with recurrent mutations identified from exome
screens of idiopathic autism.11–14 Within 10q23, we iden-
tified a smaller duplication within NRG3, a schizophrenia-
associated signaling molecule that binds and activates
ErbB4, a receptor implicated in cellular proliferation,
migration, and differentiation.54,55 If the duplicated
exon were transcribed, it would create an in-frame dupli-
cation of ten amino acids within the ErbB4-binding
domain. Additionally, although CHRNA7 (MIM 118511)
has been previously implicated as contributing to neuro-
logical defects at the 15q13.3 locus,56 in our cohort we
identified no deletions of this gene; instead, we identified
five cases with deletions of a different gene, TRPM1, at
this locus; these included a homozygous deletion not
observed in any controls. Although appealing candidates,
all of the atypical CNVs discovered within these 17
regions were inherited from unaffected parents, in
contrast to the typical larger hotspot events that were de
novo more than 50% of the time. If multiple genes within
a critical region are required for an autism phenotype, it
might be that some of these genomic hotspots will never
be refined by smaller atypical CNVs. This is consistent
with recent experimental data that suggest that syner-
gistic combinations of downregulated genes in cis are
required for recapitulation of some phenotypes of the
16p11.2 deletion,38 one of the most frequent CNVs asso-
ciated with autism.
Additional smaller recurrent CNVs were also identified
in this study outside of typical genomic hotspot regions
as a result of our backbone of genomic probes. These
included, for example, two recurrent de novo deletions
involving Neurexin1 (NRXN1)—a gene with a longstand-
ing association with autism—as well as single de novo
mutations in GABRB3 (MIM 137192) and DOCK1 (MIM
601403). Recurrent inherited mutations and de novo7, 2013
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Figure 5. Autism Candidate Genes Enriched for Copy-Number Variants in Cases versus Controls
Atypical deletions of TRPM1 (A) were observed in cases but not in controls within the 15q13.3 microdeletion locus. Targeted genotyping
of autism candidate genes DPP10 (B), NRXN1 (C), PLCB1 (D), FHIT (E), andMBD5 (F) revealed multiple deletions (red) and duplications
(blue) of genes observed in cases at a higher frequency than in controls. Blue (duplication) and red (deletion) histograms depict log2
relative hybridization signals.mutations were observed in other strong autism candi-
dates, such as PARK2, CNR1, MCPH1, and DPP10, and
reached nominal significance in comparison to controls.The AmericThe finding of three disruptive SD-associated CNVs of
HYDIN is particularly interesting because the gene has
been reported to cause hydrocephalus and impairedan Journal of Human Genetics 92, 221–237, February 7, 2013 231
Table 3. Autism Candidate Genes Enriched for Exon-Disrupting CNVs in Cases versus Controls
Candidate
Gene(s)
Autism Cases (n ¼ 2,588) Controls (n ¼ 580) WTCCC Controls (n ¼ 2,090)
Enriched
Event p ValueaDeletions Duplications Total Deletions Duplications Total Deletions Duplications Total
A2BP1 6 0 6 0 0 0 6 0 6 del 0.591
ANO5 0 1 1 1 0 0 0 0 0 dup n/a
CACNA2D3 1 0 1 0 0 0 0 0 0 del n/a
CADPS2 0 1 1 0 0 0 0 0 0 dup n/a
CNR1 0 7 7 0 1 1 0 0 0 dup 0.032
CNTNAP2 1 1 2 0 0 0 0 0 0 del/dup 0.242
CTNNA3b 21 1 22 4 0 4 8 0 8 del/dup 0.050
CTNND2b 1 0 1 0 0 0 0 0 0 del n/a
DIAPH3 1 0 1 0 0 0 2 0 2 del 0.869
DISC1 2 5 7 0 3 0 0 0 0 del 0.242
DNAH5 0 1 1 0 0 0 0 0 0 dup n/a
DOCK1b 2 0 2 0 0 0 0 0 0 del 0.242
DPP10 0 5 5 0 0 0 0 0 0 dup 0.029
DPP6 1 4 5 0 1 1 0 0 0 del/dup 0.102
EML1 0 4 4 0 0 0 0 1 1 dup 0.178
EPHA6 0 1 1 0 0 0 0 0 0 dup n/a
ERBB4 1 0 1 0 0 0 0 0 0 del n/a
F13A1b 0 1 1 0 0 0 0 0 0 dup n/a
FHITc 2 1 3 0 0 0 2 0 2 del/dup 0.485
FOXP1 2 0 2 0 0 0 0 0 0 del 0.242
GABRB3b 0 1 1 0 0 0 0 0 0 dup n/a
GALNT13 1 0 1 0 0 0 1 0 1 del 0.742
GIMAP8 1 0 1 0 0 0 0 0 0 del n/a
GPC6 1 0 1 0 0 0 0 0 0 del n/a
GRID2b 1 1 2 0 0 0 0 0 0 del/dup 0.242
GRIN2A 0 1 1 0 0 0 0 0 0 dup n/a
HYDINc 1 2 3 0 0 0 0 0 0 del/dup 0.119
IARSb 0 2 2 0 0 0 0 0 0 dup 0.242
ICA1, NXPH1 0 3 3 0 0 0 0 0 0 dup 0.119
IQGAP2 1 0 1 0 0 0 0 0 0 del n/a
KANK1 2 6 8 0 1 1 0 2 2 del/dup 0.103
KHDRBS2 0 3 3 0 0 0 1 2 3 dup 0.641
KIAA1586 3 5 8 1 0 1 1 0 1 del/dup 0.049
MBD5b 2 1 3 0 0 0 1 0 1 del 0.301
MCC 2 0 2 0 1 0 1 1 1 del 0.488
MCPH1 2 2 4 0 0 0 0 0 0 del/dup 0.059
MCPH1, DLGAP2 1 0 1 0 0 0 0 0 0 del n/a
MET 0 1 1 0 0 0 0 0 0 dup n/a
MKL2 0 1 1 0 0 0 0 0 0 dup n/a
MLL3b 1 1 1 0 1 0 0 0 0 del n/a
(Continued on next page)
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Table 3. Continued
Candidate
Gene(s)
Autism Cases (n ¼ 2,588) Controls (n ¼ 580) WTCCC Controls (n ¼ 2,090)
Enriched
Event p ValueaDeletions Duplications Total Deletions Duplications Total Deletions Duplications Total
MLL5 0 1 1 0 0 0 0 0 0 dup n/a
MPHOSPH8b 0 3 3 0 0 0 0 0 0 dup 0.119
NLGN1 0 1 1 0 0 0 0 0 0 dup n/a
NRXN1c 7 0 7 0 0 0 1 0 1 del 0.032
NRXN3 1 0 1 0 0 0 0 0 0 del n/a
NTRK3 1 0 1 0 0 0 0 0 0 del n/a
NXPH1 1 0 1 0 0 0 0 0 0 del n/a
PARK2b 12 12 24 1 2 3 4 3 7 del/dup 0.009
PCDH9 0 1 1 0 0 0 0 0 0 dup n/a
PDE4A 0 1 1 0 0 0 0 0 0 dup n/a
PLCB1 2 4 6 0 0 0 0 2 2 del/dup 0.134
POGZ 0 1 1 0 0 0 0 0 0 dup n/a
RGS7 0 1 1 0 0 0 0 1 1 dup 0.742
ROBO1b 1 1 2 0 0 0 0 0 0 del/dup 0.242
RSRC1 0 1 1 0 0 0 0 0 0 dup n/a
SEMA5A 1 0 1 0 0 0 1 1 2 del 0.869
SLC1A1 0 2 2 0 0 0 0 0 0 dup 0.242
TBC1D4 1 0 1 0 0 0 0 0 0 del n/a
THSD7A 0 1 1 0 0 0 0 2 2 dup 0.869
ZMYND11b 0 2 2 0 0 0 0 0 0 dup 0.242
ap value determined by a Fisher’s exact test.
bCandidate genes with private de novo events.
cCandidate genes with recurrent de novo events. See Table S11 for a complete list of CNVs.ciliary motility in mice 57 but has never been associated
with autism. In our study, the two de novo events are
found in probands from simplex autism families, whereas
the inherited event segregates with the disease in a multi-
plex family.
In summary, we have comprehensively characterized
recurrent CNVs for both large and putative smaller hot-
spots across the human genome. Irrespective of the size
of the hotspot, our analysis shows that both sequence
identity and the size of flanking repetitive sequences are
key determinants in their mutability. Although smaller
hotspots contribute to CNVs, we do not observe in aggre-
gate an increased CNV burden for the mini- and micro-
hotspot regions. This is in contrast to larger hotspot
regions, for which there is a clear increase in CNV burden
in children with ASD. Moreover, no recurrent larger hot-
spots appear to be specific to autism as opposed to intel-
lectual disability, although some, such as the 1q21 dupli-
cation, appear to be significantly enriched. Although
some hotspots have been refined to a single or few candi-
date genes by atypical events, we note that most of these
smaller regions of overlap correspond to genomic disor-The Americders associated with recognizable syndromic diseases.7–10
Failure of the current study as well as previous reports to
refine most testable candidate gene(s) in autism suggests
that a genomic imbalance of multiple genes could be
necessary for the manifestation of autism pheno-
types.35,58 Consistent with this model, we present quanti-
tative evidence for a phenotypic dependence on the size
of the CNV. An increasing size of deletions correlates
with a significant decrease in NVIQ, but the same effect
is not observed for an increasing size of CNV duplications,
although the latter might correspond with increased
behavioral deficits (other than IQ) in children with
autism. We predict that such recurrent CNVs will
contribute to disease risk and that the identification of
such de facto hotspots will be important in proving their
pathogenic relevance. Because many of the individuals
characterized here for CNVs are now part of ongoing
exome11–14 and genome sequencing studies, it will be crit-
ical to integrate these CNV data with other disruptive in-
herited and de novo substitutions and indel mutations59
in order to provide a more complete picture of the genetic
etiology of autism.an Journal of Human Genetics 92, 221–237, February 7, 2013 233
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Figure 6. SD-Associated Copy-Number Variants of HYDIN
A de novo deletion and duplication, as well as an inherited duplication, were identified in children with autism. The child with the in-
herited duplication shares the event with his affected identical twin, but not with his unaffected sibling. Though these events are large
and encompass numerous genes, the de novo duplication directly breaksHYDIN. Blue (duplication) and red (deletion) histograms depict
log2 relative hybridization signals.Supplemental Data
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